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RESUMO 
As células tumorais apresentam um metabolismo alterado, com um aumento da taxa de 
captação de glucose e produção de lactato relativamente ao metabolismo oxidativo 
(efeito de Warburg). Os polifenóis alimentares são conhecidos por possuírem efeitos 
quimiopreventivos e anticancerígenos. Recentemente, o nosso grupo verificou que os 
polifenóis quercetina (um flavanol) e a epigalocatequina-3-galato (um flavan-3-ol) inibem 
a captação de glucose em células de cancro da mama (células MCF-7). Por esta razão, 
decidiu-se investigar se outros polifenóis interferem também com a captação de glucose 
nestas células. Os polifenóis testados foram outros flavanóis (miricetina e kaempferol) e 
flavan-3-óis ((+) catequina e (-) epicatequina), uma flavona (crisina), uma isoflavona 
(genisteina), uma chalcona (xantohumol) e um stilbeno (resveratrol). 
A captação de 3H-desoxi-D-glucose (3H-DG) pelas células MCF-7 foi dependente do 
tempo e saturável (Km=6.5±0.5 mM e Vmáx=63.6±2.3 nmol/mg prot). 
Agudamente (26 min), a miricetina (10-100 µM), a crisina (100 µM), a genisteína (10-100 
µM), o resveratrol (10-100 µM), o kaempferol (10-100 µM) e o xantohumol (10-100 µM) 
inibiram a captação de 3H-DG. Por outro lado, a (+) catequina e a (-) epicatequina 
aumentaram-na ligeiramente (10-15%). Verificou-se que o kaempferol foi o inibidor mais 
potente da captação de 3H-DG nas células MCF-7, com um IC50 de 4.0 (1.6-9.8) µM (o 
IC50 da genisteína e do resveratrol foram 38.9 (15.2-99.4) µM e 67.2 (29.4-153.7) µM, 
respectivamente). O kaempferol (100 µM) comporta-se como um inibidor misto, uma vez 
que, aumenta o Km (para 15.6± 2.4 mM) e simultaneamente o Vmáx (para 106.9± 10.6 
nmol/mg prot). 
Cronicamente (24 h), o kaempferol foi também capaz de inibir a captação de 3H-DG (IC50 
de 13.6 (2.8-66.9) µM). Este flavonóide inibiu em cerca de 40% a transcrição do GLUT e, 
apesar de não significativo, este efeito foi acompanhado pela diminuição de produção 
proteica do GLUT1. Verificou-se ainda que a exposição das células ao kaempferol induziu 
um aumento dos níveis de lactato extracelular ao longo do tempo, o que sugere que este 
flavonóide inibe a recaptação de lactato através da inibição do MCT1. 
Adicionalmente, o kaempferol revelou propriedades antiproliferativas e citotóxicas, uma 
vez que foi capaz de inibir o crescimento e reduzir a viabilidade celular. Estes efeitos do 
kaempferol foram mimetizados com uma concentração baixa de glucose no meio 
extracelular e foram revertidos com uma concentração alta de glicose no meio 
extracelular.  
Em conclusão, o kaempferol (e, embora menos potentemente, alguns dos outros 
polifenóis) inibe a captação de glucose nas células MCF-7 de uma forma potente, 
aparentemente por bloqueio de membros da família GLUT de transportadores de glicose 
 x 
 
(muito provavelmente o GLUT1). Este efeito parece contribuir para o efeito 
quimiopreventivo deste composto presente na dieta.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Palavras-Chave ∙ Células do Cancro da Mama ∙ Absorção de Glicose ∙ Polifenóis ∙ 
Kaempferol 
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ABSTRACT 
Cancer cells present an altered metabolism, with an increased rate of glucose uptake and 
lactate production instead of oxidative metabolism (the Warburg effect). Dietary 
polyphenols are known to possess cancer preventive and anticancer effects. Recently, 
our group verified that the polyphenols quercetin (a flavanol) and epigallocatechin-3-
gallate (a flavan-3-ol) inhibited glucose uptake by the MCF-7 breast cancer cell line. So, 
we decided to investigate if other polyphenols could also interfere with glucose uptake by 
these cells. The polyphenols tested were other flavanols (myricetin and kaempferol) and 
flavan-3-ols ((+) catechin and (-) epicatechin), a flavone (chrysin) and an isoflavone 
(genistein), a chalchone (xanthohumol) and a stilbene (resveratrol). 
Uptake of 3H-deoxy-D-glucose (3H-DG) by MCF-7 cells was time-dependent and saturable 
(Km=6.5±0.5 mM and Vmáx=63.6±2.3 nmol/mg prot).  
Acutely (26 min), myricetin (10-100 µM), chrysin (100 µM), genistein (10-100 µM), 
resveratrol (10-100 µM), kaempferol (10-100 µM) and xanthohumol (10-100 µM) inhibited 
3H-DG uptake. By contrast, (+) catechin and (-) epicatechin slightly (by 10-15%) increased 
it. Kaempferol was found to be the most potent inhibitor of 3H-DG uptake by MCF-7 cells, 
with an IC50 of 4.0 (1.6-9.8) µM (the IC50 of genistein and resveratrol was 38.9 (15.2-99.4) 
µM and 67.2 (29.4-153.7) µM, respectively). Kaempferol (100 µM) behaved as a mixed-
type inhibitor, since it simultaneously increased the Km (to 15.6±2.4 mM) and the Vmáx (to 
106.9±10.6 nmol/mg prot).  
Chronically (24h), kaempferol was also able to inhibit 3H-DG uptake (IC50 of 13.6 (2.8-
66.9) µM). This flavonoid was also found to inhibit by around 40% GLUT1 transcription 
and, although not statistically significant, this effect was accompanied by a decrease in 
GLUT1 protein production. We also verified that exposure of cells to kaempferol induced 
an increase in extracellular lactate levels over time which suggests that this flavanol 
inhibits lactate reuptake by inhibiting MCT1. 
Additionally, kaempferol revealed antiproliferative and cytotoxic properties, because it 
inhibited cell growth and decreased cell viability. These effects of kaempferol were 
mimicked with low extracellular glucose conditions and reversed with high glucose 
extracellular conditions.  
In conclusion, kaempferol (and, albeit less potently, some other polyphenols) potently 
inhibits glucose uptake by MCF7 cells, apparently by blocking members of the GLUT 
family (most probably GLUT1). This effect may contribute to the known chemopreventive 
effect of this dietary compound. 
Keywords ∙ Breast Cancer Cells ∙ Glucose uptake ∙ Polyphenols ∙ Kaempferol  
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1. BREAST CANCER 
 
 
1.1 Characteristics and Epidemiology 
 
Breast Cancer (BrC) is the most common malignancy in women and its incidence has 
been increasing over the years, especially in older women (1-3). It is the fifth most 
common cause of cancer death, lung cancer being on top of the list (4). In Portugal, 4 500 
new cases are estimated to appear every year with a corresponding mortality of 1 500 (2). 
Fortunately, the death rate for breast cancer has been decreasing over the past decade, 
since there are faster and more efficient diagnostic methods and improved therapies. 
Also, divulgation about the symptoms and self-exams is as important as knowledge about 
risk factors, because it is estimated that about 90% of breast cancer could be treated and 
consequently curable if they are detected in an early stage (2).  
Ninety five percent of breast cancers are carcinomas, since they arise from breast 
epithelial elements (3, 5). Normally, 85% of breast carcinomas originate in cells of ducts 
(ductal carcinoma) and 15% begin in the cells that line the lobules (lobular carcinoma). 
Non-carcinomatous breast cancers are rare and originate in the connective tissue of the 
breast (1, 3).   
Cancer cells present some characteristics that distinguish them from normal cells, 
including loss of differentiation, uncontrolled growth, immortalization, loss of contact 
inhibition, increased invasive capacity, evasion from the host immune surveillance 
processes and the apoptotic signal restraints and induction of neo-angiogenesis (6, 7).  
Cancer is a multistep process that includes initiation, proliferation and progression. Breast 
cancer carcinogenesis begins with an increase in the number of breast cells (hyperplasia), 
followed by the emergence of atypical breast cells (atypical hyperplasia), carcinoma in situ 
(noninvasive cancer) and finally, invasive cancer (Fig. 1) (3). 
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Figure 1: Model of the multistep carcinogenesis in BrC. DCIS: ductal carcinoma in situ; LCIS: lobular 
carcinoma in situ; IDC: invasive ductal carcinoma; ILC: invasive lobular carcinoma. Adapted from Bechmann 
et al. (1997). 
 
 
Not all BrC necessarily follow this progressive pattern and the same speed of progression, 
so some cancers may never progress beyond in situ disease (3), staying at stage 0 as 
shown in Table 1. Thus, BrC may be invasive, when they spread from the milk duct or 
lobule to other tissues in breast; or noninvasive (in situ), if remain confined to the ductal or 
lobular epithelium.  
 
 
Table 1: Staging of Breast Cancer. Adapted from Kumar et al. (2010)  
Stage T: Primary Cancer N: Lymph Nodes 
M: Distant 
Metastasis 
5-Year 
Survival (%) 
0 DCIS or LCIS No metastases Absent 92 
I Invasive carcinoma ≤2 cm No metastases Absent 87 
II 
Invasive carcinoma >2 cm No metastases Absent 
75 
Invasive carcinoma <5 cm 1 to 3 positive Absent 
III 
Invasive carcinoma >5 cm 1 to 3 positive Absent 
46 
Any size invasive carcinoma ≥4 positive Absent 
Invasive carcinoma with skin 
or chest wall involvement or 
inflammatory carcinoma 
0 to >10 positive Absent 
IV Any size invasive carcinoma 
Negative or positive 
lymph nodes 
Present 13 
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1.2 Risk Factors and Etiology  
 
Breast carcinomas can be divided into sporadic and hereditary cases. The first ones 
correspond to the majority of all BrC cases and are associated with somatic genetic 
alterations, probably related to hormonal exposure, diet and lifestyle. Hereditary cases, on 
the other hand, are associated with germline mutations. The probability of a hereditary 
etiology increases with multiple affected first-degree relatives, when individuals are 
affected before menopause and/or have multiple cancers, or there are family members 
with other specific cancers. The inheritance of a susceptibility gene is the primary cause of 
approximately 12% of BrC (3, 8). 
Women with an inherited BRCA1 or BRCA2 mutation have a greatly increased risk of 
developing BrC. Mutations in BRCA1 or BRCA2 are responsible for 52% and 32% of 
hereditary BrC cases, respectively. However, BRCA1 mutations also increase the 
susceptibility to ovarian cancer and the mutation in BRCA2 is frequently associated with 
male breast cancer. These two are the most common genes related to hereditary BrC, but 
other genes are also associated, such as ATM, CHEK2, RAD51, AR, DIRAS3, ERBB2, 
and TP53 (9).  
Beyond this, BrC tumor type and degree of aggressiveness can be affected by age and 
gender, family and personal history, radiation, microenvironment and diet factors (3). 
It is known that many aspects of women's diets and lifestyle have an effect on increasing 
or decreasing BrC risk. It is proved that obese women (especially after menopause) have 
an increased risk of BrC. Because our organism produces some estrogen in fat tissue, it is 
therefore more likely that obese women exhibit high levels of estrogen and, consequently, 
increased risk for breast cancer (2). Studies suggest that heavy cigarette smoking and 
high exposure to tobacco smoke are associated with an increase in BrC risk. On the other 
hand, physical activity can help to reduce it (10).  
Diet has also an important role in promotion or inhibition of tumor progression. Factors like 
low dietary folate levels, high consumption of soy products, red meat or well-done meat 
and dairy products are under study for an association with an increase in BrC risk (2, 3). It 
is estimated that a 40% increase in BrC risk is associated with having 2 to 5 alcoholic 
drinks per day, although this effect can be counterbalanced with a high folic acid 
consumption (11). Some more dietary factors are known to decrease the risk, such as 
high consumption of fruits and vegetables, caffeine and large amounts of fiber (10). 
In summary, ~20% of all cancers are caused by diet and around 30–40% can be 
prevented by it (12-14). So, it is important to analyze the effects of these dietary factors at 
a molecular level. 
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2. GLUCOSE UPTAKE IN BREAST CANCER CELLS 
 
2.1 Glucose transporters 
 
Glucose has several roles in our organism, since it is a precursor of glycoproteins, 
triglycerides and glycogen. Furthermore, and very importantly, glucose oxidation is a 
major source of metabolic energy in eukaryotic cells (15, 16).  
Glucose can be synthetized within our body but it can also be obtained from the diet. 
Glucose obtained from diet is transferred from the lumen of the small intestine into the 
blood circulation, where it is transported together with glucose synthesized within the 
body. Since glucose (as the other sugars) is hydrophilic, it cannot enter the cell by simple 
diffusion and needs some specific transporters to cross the hydrophobic plasma 
membranes. In humans and other mammals, these transporters correspond to the 
Facilitative Glucose Transporters (GLUTs) and the Sodium-dependent Glucose 
Transporters (SGLTs) (15). 
 
 
  2.2 Facilitative Glucose Transporters (GLUTs) 
The facilitative glucose transporters (GLUT) move sugars across cell membrane in favor 
of concentration gradient and without energy consumption (17).  
The GLUT family of transporters is encoded by the SLC2A gene family that possesses 14 
members. GLUTs are all intrinsic membrane proteins and they differ in their tissue 
distribution, having different affinities for sugars and responding to metabolic and 
hormonal regulation (16, 18). 
Some models have been proposed indicating the orientation of GLUTs in the cell 
membrane. Macheda et al. (2005) suggest that the protein traverses the cell membrane 
12 times, with the NH2
- and COOH- termini of the protein located on the cytoplasmic side 
of the membrane and a large intracellular loop between transmembrane domains (TM) 6 
and 7 (Fig. 2) (19). 
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GLUT family members are divided into three classes according to the loop position and to 
their structural characteristics. We will next refer the GLUT members known to be present 
in MCF-7 cells (16, 20).  
The class I and II have an extracellular loop between TMs 1 and 2 that contains an N-
linked glycosylation site. Despite this similarity, these classes present several differences 
in terms of structure, function and tissue distribution (15).      
The class I is constituted by GLUT1, GLUT2, GLUT3 and GLUT4.  
The first member of this class, GLUT1, is normally found in brain, breast, erythrocytes, 
adipose tissue and it is believed that GLUT1 is responsible for basal glucose uptake in 
most tissues (17). This transporter is also present and even overexpressed in most 
cancers. It is highly expressed in cancers with higher grade and proliferative index and 
lower degree of differentiation. Thereby, it is associated with increased malignant 
potential, invasiveness and consequently, poor prognosis (18). Macheda et al. (2005) 
demonstrated that glycosylation of GLUT1 in between transmembrane domains 1 and 2, 
increases the efficiency of glucose transport. These same authors also show that hypoxia, 
estradiol and epidermal growth factor, which have an important role in BrC growth, can 
increase GLUT1 levels and glucose uptake in these cells (19).  
GLUT2 is expressed in pancreatic β cells, liver and kidneys. It is thought that GLUT2 in β 
cells is important for the glucose-sensing mechanism of these cells and in bidirectional 
transport of glucose under hormonal control, in the liver. This glucose transporter is also 
characterized by its ability to transport fructose and is found on the surface of proximal 
renal tubules and enterocytes (15, 20).  
Figure 2: Model of the orientation of facilitative glucose transporter proteins in the cell membrane. Adapted 
from Macheda, M., et al., (2005). 
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GLUT3 is also present in most cancers but not so frequently as GLUT1. The affinity of 
GLUT3 to glucose is the highest of all GLUTs, and it is present in tissues with high 
necessity of fuel, such as brain (15, 18, 20).  
GLUT4 is mostly found in heart, skeletal muscle and adipose tissue. In the presence of 
insulin, GLUT4 is translocated from vesicles of intracellular compartments to the cell 
membrane, resulting in 10-20 fold increase in glucose transport (19, 21).  
 
GLUT5, GLUT7, GLUT9 and GLUT11 belong to class II.  
GLUT5 only accepts fructose as a substrate, and it is responsible for fructose absorption 
in the small intestine. The presence of GLUT5 was observed in human BrC tissue, but not 
in normal breast tissue, indicating that fructose may play an important role in tumor growth 
(19). It is also present in small intestine, testes and kidneys. 
 
The class III members lack the extracellular loop between TMs1 and 2 but contain a large 
extracellular loop and potential sites of N-linked glycosylation between TMs9 and 10. 
Apart from this, all members of this class (GLUT6, GLUT8, GLUT10, GLUT12 and HMIT) 
contain targeting amino acid sequences. 
Similarly to GLUT4, GLUT12 is expressed in insulin-sensitive tissues, being translocated 
to the cell membrane in the presence of insulin. Studies suggest that GLUT12 was found 
in a human breast cancer cell line but is also expressed in the rat lactating mammary 
gland. This  is considered a reactive gene since it is expressed in the embryo and down-
regulated in adult tissues (19). 
 
 
2.3 Sodium-dependent Transporters (SGLT) 
This family of transporters transports glucose via a secondary active transport 
mechanism. The Na+ electrochemical gradient provided by the Na+ - K+ ATPase pump is 
used to transport glucose into cells against its concentration gradient. There are 12 
members of the human family, encoded by the SLC5A gene family (16). 
SGLT1 moves glucose and also galactose (although with a much lower affinity) and is the 
only expressed in the small intestine. This member is also responsible for the recovery of 
any remaining glucose to avoid glucose loss in the urine (15, 22).  
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 2.4 The Warburg effect 
In normal cells, glucose is converted into pyruvate through glycolysis, and consequently 
into acetyl-CoA, which is used by the mitochondria to produce ATP. On the other hand, in 
poorly oxygenated cells or in cells that lack mitochondria, pyruvate is converted to lactate 
which is normally released from the cell. However, cancer cells present an altered 
metabolism, and therefore an increased lactate production even in the presence of 
oxygen. This is known as the Warburg effect. These cells present an increased rate of 
glucose uptake for ATP production, since the lack of  oxygen supply contributes to an 
hypoxic microenvironment, which upregulates GLUT expression and lactate secretion 
(16). 
The Warburg effect was observed for the first time by Otto Warburg in the first half of the 
20th century (23). This concept defines increased rates of glycolysis in the presence of 
adequate O2 levels in cancer and non-transformed proliferating cells. 
At the beginning this effect was thought to be caused by irreversible damage of oxidative 
phosphorylation (OXPHOS). However, this explanation was refutable after the observation 
of the Warburg effect in non-transformed proliferating cells, since these are not supposed 
to have irreversible damages on OXPHOS. 
Cancer cells activate glycolysis in presence of O2 to get a powerful growth advantage, 
faster ATP generation and to provide carbon skeletons for biosynthesis. Furthermore, 
some data suggest that the activation of glycolysis have an important role in the protection 
against cell death induced by ROS. Also, the persistent activation of glycolysis leads to 
environmental acidosis, which is toxic to normal cells and contributes to the tumor 
proliferation.  
Most cancers have the following characteristics: overexpression of HIF-1, alkaline 
intracellular pH values, high generation of O2
•- and H2O2 and alterations in OXPHOS. So, 
hypoxia and activation of HIF-1 play an important role in cancer cell metabolism, since 
they contribute the switch from OXPHOS to glycolysis (24).  
Moreover, high levels of glucose transporters expression are associated with cancers of 
higher grade and proliferative index and in cancers of lower degree of differentiation. This 
is most probably related to the Warburg effect (18, 25).  
With these evidences, some studies suggest that the upregulation of specific glucose 
transporters and the Warburg effect may be the key for the tumor surveillance and growth 
(18). 
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 2.5 Glucose transport and BrC 
Similarly to all cancer cells, BrC cells exhibit a high glycolytic activity compared with 
normal tissues. In BrC, glucose transport activity is strongly correlated with increased 
GLUT1 expression (26). GLUT1 is seen as a marker in early diagnosis as well as a new 
potencial therapeutic target. This transporter is a marker of hypoxia and glucose 
metabolism, and normally it is associated to a poor prognosis (16). 
Nowadays, cancer therapy is based on two approaches: (1) conventional chemotherapy – 
an unspecific process that reaches all type of cells, eg. drugs that block nucleotide 
biosynthesis; and (2) targeted therapy – drugs designed to block specific components. 
Examples of the last one are: mTORC inhibitors (reduce glucose uptake), antisense 
oligonucleotides (downregulate the mRNA and protein expression of GLUT1), inhibitors of 
lactate dehydrogenase and monocarboxylate transporters, and anti-GLUT antibodies 
(induce growth arrest and apoptosis). The last one inhibits around 75% of breast cancer 
cell proliferation (16, 17, 25).  
According to Aft et al. (2002), 2-deoxy-D-glucose (2-DG) strongly inhibits glucose 
metabolism and ATP production, causing growth inhibition and apoptosis. 2-DG is a 
structural analogue of glucose differing at the substitution of hydrogen for a hydroxyl 
group in the second carbon atom (Fig. 3). This modification causes an increased uptake, 
high intracellular levels of hexokinase or phosphorylating activity and low intracellular 
levels of phosphates, which lead to metabolic trapping (27). So, 2-DG is a promising 
agent to treat solid tumors, since it increases the efficiency of other therapies (17).   
 
 
 
 
 
 
 
 
 
Figure 3: Structural comparison of glucose (left side) and 2-deoxy-D-glucose (right side).  
 
 
 
 
 
Glucose 
H 
2- deoxy-D-glucose 
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3. POLYPHENOLS AS ANTICARCINOGENIC AGENTS 
 
 3.1 Polyphenol classes and anticarcinogenic effects 
Several dietary compounds including vegetables, fruits and beverages are rich in 
polyphenols, which are secondary metabolites produced as a response to ultraviolet 
radiation, aggression by pathogens, disease, injury or stress (28). It is estimated that the 
total dietary intake is around 1g of polyphenols per day, wherein two-third are flavonoids 
and the remainder phenolic acids and other non-flavonoids (29, 30). 
Polyphenols are constituted by at least one aromatic ring with one or more hydroxyl 
attached and can be classified into Flavonoids and Non Flavonoids according to their 
chemical structure and complexity (Fig. 4) (31, 32). Flavonoids are also classified 
according to their different characteristics: flavones are the most hydrophobic and 
isoflavones present structural similarities to estrogens. 
 
 
 
 
 
 
 
Figure 4: Schematic representation of the classes and subclasses of polyphenols. 
 
Initially, the protective effect of dietary polyphenols was thought to be due to their 
antioxidant properties, which decreased free radicals levels within the body. Another 
antioxidant mechanism is the chelation of metals such as iron and copper ions, which 
prevent their participation in Fenton-type reactions and the generation of highly reactive 
hydroxyl radicals (33).  
These are known to reduce the incidence of diseases, such as cardiovascular diseases, 
diabetes and cancer (31). Several epidemiological studies have found an association 
between certain foods rich in polyphenols, specially flavonoids, and a decrease in 
incidence of some types of cancer (renal cell carcinoma, breast, ovarian and colorectal) 
(34). Obviously, the health effects of polyphenols are influenced by the amount consumed 
and by their bioavailability (28). 
Certain dietary phenolic and their metabolites are able to modulate cell functions such as 
growth, proliferation, angiogenesis and apoptosis. The chemopreventive effect of some 
polyphenols appears to be related to the fact that they (1) inhibit carcinogen activation, 
catalyzed by cytochrome p450 enzymes (CYP450), (2) induce phase II enzymes, which 
Flavonoids 
Flavonols 
 
Flavan-3-ols 
 
Flavones 
 
Flavanones 
 Chalcones 
 
Isoflavones 
 
Anthocyanidins 
 
Non 
Flavonoids 
Lignans 
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Phenolic acids 
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facilitate the elimination of certain carcinogens, (3) have antioxidant effect (35, 36). 
Beyond this, polyphenols can inhibit the metabolism of arachidonic acid, which is 
important to the production of many proinflammatory metabolites such as certain 
prostaglandins and leukotrienes (37). They are also the ability to interact with intracellular 
signaling cascades and with some pathways, such as NF-kB, activate protein-1 and 
mitogen-activated protein kinase (MAPK) (31, 38). 
 
 
3.2 Flavonoids 
Flavonoids are constituted by two aromatic rings connected by a heterocyclic ring: C6-C3-
C6 and usually they are conjugated to sugars (39). Depending on the classification 
method, the flavonoid group can be divided into several categories based on 
hydroxylation of the flavonoid nucleus as well as the linked sugar: flavonols, flavan-3-ols, 
flavones, isoflavones, flavanones, anthocyanidins and chalcones. In the present work, we 
studied the flavonoids present in Table 2 only. All these compounds were previously 
demonstrated to have an anticarcinogenic effect and they are present in high amounts in 
the human diet (their consumption varies between 26 mg and 1g per day) (39). 
 
Table 2: Chemical structures of some selected flavonoids (29) 
Subclass of 
flavonoids 
Molecular 
Structure 
Functional groups and 
examples 
Source 
Flavonols 
 
 
R1=H; R2=OH; R3=H: kaempferol 
R1=OH; R2=OH; R3=OH: myricetin 
 
Yellow onion, Curly kale,   
Leek, Cherry tomato, 
Broccoli, Blueberry, Black 
currant, Apricot, Apple,  
Beans, Black grape, 
Tomato, Black and Green 
tea infusion, Red wine 
 
Flavan-3-ols 
 
Monomeric 
R1=H; R2=OH; R3=H: (+)catechin 
R1=OH; R2=H; R3=H: (-)epicatechin 
Chocolate, Beans, Apricot, 
Cherry, Grape, Peach, 
Blackberry, Apple, Black 
and Green tea, Red wine  
Flavones 
 
chrysin Parsley, Celery,  Pepper 
Isoflavones 
 
R2=OH: genistein 
Soy flour, Soybeans, Miso, 
Tofu , Tempeh, Soy milk 
Chalcones 
 
xanthohumol Beer 
O
OOH
OH
R1
R2
R3
OH
O
R1
R2
OH
OH
OH
OH
R3
O
OOH
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  3.3 Non Flavonoids 
 
Non-flavonoids are structurally constituted by two aromatic rings connected by C6-C2-C6. 
This group is divided into: phenolic acids, stilbenes and ligans. The main member of this 
class is resveratrol, a stilbene (Table 3), and its trans conformation has the ability to inhibit 
carcinogenesis (31). 
 
Table 3: Chemical structure of the non-flavonoid resveratrol (29) 
Subclass of non-
flavonoid 
Molecular 
Structure 
Functional groups and 
examples 
Sources 
Stilbenes 
 
resveratrol Red wine, peanuts 
 
 
4. AIM 
Recently, our group verified that the polyphenols quercetin (a flavanol) and 
epigallocatechin gallate (a flavan-3-ol) inhibited glucose uptake by the breast cancer 
(MCF-7) cells (21). 
So, in the present work, we decided to investigate if other polyphenolic compounds could 
also interfere with glucose uptake by MCF-7 cells and, if so, if this effect is involved in 
their anticarcinogenic activity. 
We decided to test the effect of kaempferol (KF) and myricetin (two flavonols). Flavonols 
are the most abundant polyphenolics in food, KF being the main member of this class. 
According to Shiomi et al. (2013), myricetin can inhibit mammalian DNA polymerase, 
topoisomerase and human cancer cell proliferation (40). In addition, myricetin and KF can 
inhibit glucose efflux in human erythrocytes (39). 
We also tested the effect of (+) catechin and (-) epicatechin (two flavan-3-ols). Studies 
show that (+) catechin inhibit HGF/Met signaling in immortalized and tumorigenic breast 
epithelial cells and suppress MCF-7 proliferation through TP53/caspase-mediated 
apoptosis; while (-) epicatechin have a potent and antiproliferative activity in human BrC 
cells (41-43). 
A flavone member, chrysin, and an isoflavone, genistein, were also included in this study. 
Despite less common in fruits and vegetables, chrysin have also an important paper in 
cancer therapy. Several studies suggest that chrysin is able to inhibit aromatase in MCF-
7, to induce apoptosis and to be an adjuvant in anti-cancer therapy (44). Li et al. (2013) 
OH
OH
OH
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concluded that epigenetic processes are the most important mechanism involved in the 
inhibition of BrC by genistein (45). Isoflavones reduce the incidence of BrC, due to their 
competition with oestrogens, inhibiting tumor growth, which is dependent on oestrogens 
(31). 
Xanthohumol, a member of the chalcones family was also studied. Monteiro et al. (2008) 
studied the effect of xanthohumol in BrC xenografts in nude mice and noticed that this 
compound has antiangiogenic, antiproliferative and anti-inflammatory effects (46). 
Finally, a member of stilbenes, resveratrol, was also included. Su et al. (2013) shows the 
antioxidant and antiproliferative properties of resveratrol, and the fact that it reduces the 
viability, arresting the cell cycle in MCF-7 cells (47).  
For this purpose, the acute and chronic exposure of the mentioned polyphenols on 
glucose uptake by BrC cells (MCF-7) was investigated. The cellular viability and 
proliferation as well as mRNA and protein expression were also evaluated.  
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1. Materials 
3H-2-deoxy-D-glucose (3H-DG; specific activity 50 Ci/mmol) (American Radiolabeled 
Chemicals Inc., St. Louis, MO, USA), 3H-thymidine (methyl-[3H] thymidine; specific activity 
79 Ci/mmol) (GE Healthcare GmbH, Freiburg, Germany). Dimethyl sulfoxide (DMSO), 2-
deoxy-D-glucose, nicotinamide adenine dinucleotide (NADH), sulforhodamine B (SRB), 
cytochalasin B (from Helminthosporum dematiodium), trichloroacetic acid (TCA), Tris, 
MEM M0643 (minimum essential medium), HEPES (N-2-hydroxyethylpiperazine-N’-2-
ethanesulphonic acid), antibiotic/antimycotic solution (100 U/ml penicilin, 100 μg/ml 
streptomycin and 0.25 μg/ml amphotericinB), phloridzin, cytochalasin B, catechin, 
epicatechin, xanthohumol, chrysin, resveratrol, myricetin, genistein, kaempferol, quercetin, 
triton X-100, trypsin-EDTA solution, sodium pyruvate (Sigma, St. Louis, MO, USA). Fetal 
bovine serum (Gibco, Life Technologies Corporation, CA, USA), Tripure® (Roche 
Diagnostics, Germany). D-glucose (Merck, Germany). 
Drugs to be tested were dissolved in DMSO or ethanol. The final concentration of this 
solvent was 1% in HMBS buffer and 0.1% in culture medium. Controls for test compounds 
were run in the presence of the respective solvent. 
 
2. Methods 
 
2.1. MCF-7 cell culture 
The MCF-7 cell line was obtained from the American Type Culture Collection (ATCC 37-
HTB, Rockville, Md., USA) and was used between passage numbers 55 and 94. The cells 
were maintained in a humidified atmosphere of 5% CO2-95% air and were grown in 
minimum essential medium (MEM) containing 5.56 mM glucose and supplemented with 
10% fetal calf serum and 1% antibiotic/antimycotic solution. Culture medium was changed 
every 2 to 3 days and the culture was split every 7 days. For subculturing, the cells were 
removed enzymatically (0.25% trypsin-EDTA, 3 min, 37 ºC), split 1:6, and subcultured in 
plastic culture dishes (21 cm2; ᴓ, 60mm; TPP®, Trasadingen, Switzerland). For transport 
experiments, glucose metabolism assessment and for quantification of cell viability and 
growth, MCF-7 cells were seeded on 24-well plastic cell culture dishes (2cm2; ᴓ 16mm; 
TPP®), and were used after 6-7 days in culture (90-100% confluence). For RNA and 
protein extraction, cells were seeded in plastic culture dishes (21 cm2; ᴓ, 60mm; TPP®) 
and were used 6-7 days after seeding. In all experiments, the medium was made free of 
fetal calf serum for 24 h before the experiments. 
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2.2.  Transport studies 
In the transport assays, 3H-DG was used as a substrate. DG is an unmetabolizable D-
glucose analogue which is transported efficiently by GLUTs, but is poorly transported by 
SGLT1 (48). 
The transport experiments were performed in HMBS buffer (composition, in mM: 140 mM 
NaCl, 5 mM KCl, 12.5 mM HEPES, 12.5 mM MES, 2 mM MgCl2 and pH = 7.4). Initially the 
culture medium was aspirated and the cells (MCF-7) were washed with 0.3 ml HMBS 
buffer at 37ºC; then the cell monolayers were preincubated for 20 min in HMBS buffer at 
37ºC. Uptake was then initiated by the addition of 0.2 ml buffer at 37ºC containing 20 nM 
3H-DG (except in experiments for determination of kinetics of 3H-DG uptake). Incubation 
was stopped after 6 min (except in the time-course experiments, where incubation time 
was variable) by removing the incubation medium, placing the cells on ice and rinsing the 
cells with 0.5 ml ice-cold HMBS buffer. The cells were then solubilized with 0.3 ml 0.1 % 
(v/v) Triton X-100 (in 5 mM Tris-HCl, pH 7.4), and placed at room temperature overnight. 
Radioactivity in the cells was measured by liquid scintillation counting. 
In experiments for determination of kinetics of 3H-DG uptake, cells were incubated for 6 
min with increasing concentrations of 3H-DG: 0.02 µM, 1 µM, 10 µM, 100 µM, 300 µM, 
1000 µM, 2500 µM, 5000 µM, 10 000 µM. 
In experiments for determination of the chronic effect of compounds upon 3H-DG uptake, 
there was no preincubation period. 
 
2.3 Treatment of MCF-7 cells 
 
The concentration of compounds to be tested was chosen based on previous work of our 
group (21, 49-51). 
In order to test the acute effect of compounds, cells were exposed to the compounds 
during both the 20-min preincubation and the 6-min incubation period with 3H-DG (20 nM) 
in HMBS buffer. 
In order to test the chronic effect of compounds, cells were exposed to the compounds for 
24h in serum-free culture medium followed by a 6-min incubation period in the presence 
of 3H-DG (20 nM) in HMBS buffer. 
In some experiments, chronic treatment of the cells with kaempferol (100 µM; 24h) was 
performed in HMBS buffer with different concentrations of D-glucose (1 mM, 5.56 mM and 
20 mM). 
 
 II   MATERIALS AND METHODS 
 
21 
 
2.4 Protein determination 
 
The protein content of cell monolayers was determined by Bradford method (52), using 
serum albumin as standard. 
 
2.5 Evaluation of cellular integrity 
 
2.5.1 Determination of cellular viability (quantification of extracellular LDH activity) 
The effect of the polyphenols upon MCF-7 cellular viability was determined by using the 
lactate dehydrogenase (LDH) method. The intracellular enzyme LDH is released into the 
extracellular medium after cellular death. As described by Bergmeyer and Bernt (53), the 
activity of this enzyme is determined spectrophotometrically by measuring the decrease in 
absorbance of NADH during the reduction of pyruvate to lactate, according to the equation 
(1).   
Piruvate + NADH + H+ LDH Lactate + NAD+   (1) 
For this assay, cells were seeded on 24-well plates and submitted to acute or chronic 
treatment with polyphenols. 
After treatment, cellular leakage of the cytosolic enzyme lactate dehydrogenase (LDH) 
was determined as briefly described. 50 µl of the extracellular medium were added to 1.5 
ml of phosphate / pyruvate solution (48 mM/ 0.6 mM respectively). Then, 25 µl of NADH 
solution (0.18 mM) was added, and the absorbance values were measured for 2 min at 
340 nm. The reduction rate of absorbance was thus obtained and the enzyme activity 
calculated. Enzyme activity was expressed as the percentage of extracellular LDH activity 
in relation to the total cellular LDH activity. To determine total cellular LDH activity, control 
cells were solubilized with 0.5 mL of 0.1% (v/v) Triton X-100 (in 5 mM tris.HCl, pH 7.4) for 
30 min at 37 ºC. This LDH activity is considered the total activity, since it represents 100% 
of cellular death.  
 
2.5.2 Determination of cell growth (sulforhodamine B assay) 
At the end of acute or chronic treatment with polyphenols, 62.5 μl of icecold 50 % (w/v) 
trichloroacetic acid (TCA) were added to HMBS buffer or serum free culture medium (500 
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µl) on each well to fix cells (1 h at 4°C in the dark). The plates were then washed five 
times with tap water to remove TCA. Plates were air-dried and then stained for 15 min 
with 0.4 % (w/v) SRB dissolved in 1 % (v/v) acetic acid. SRB was removed and cultures 
were rinsed four times with 1 % (v/v) acetic acid to remove residual dye. Plates were 
again air-dried and the bound dye was then solubilized with 375 μl of 10 mM Tris–NaOH 
solution (pH 10.5). The absorbance of each well was determined at 540 nm; samples 
were diluted in order to obtain absorbance values lower than 0.7. 
 
2.6 Determination of cell proliferation rate 
Cell proliferation rate was determined by the 3H-thymidine incorporation assay. Briefly, 
MCF-7 cells treated for 24 h with kaempferol (30 or 100 µM) or DMSO were incubated 
with 3H-thymidine 0.025 µCi/ml for 5 h, in serum freeculture medium. The excess of 3H-
thymidine was removed with 300 µl of 10% trichloroacetic acid wash for 1 h at 4 ºC. After 
a 30 min drying period, 280 µl of NaOH 1 M were added, and the incorporated 3H-
thymidine was measured by liquid scintillometry. 
 
2.7 Assessment of glucose metabolism 
Glucose metabolism was assessed by quantification of lactate in the extracellular medium 
of MCF-7 cells exposed for 4 h or 24 h to kaempferol 30 µM, 2-desoxy-D-glucose (DG) 2 
mM or quercetin 100 µM (or the respective solvents) in serum free culture medium or in 
HMBS buffer with 5 mM D-glucose. Extracellular medium was collected and centrifuged at 
8000 g for 10 min. Lactate concentration was then measured by the lactate 
oxidase/peroxidase colorimetric assay, as indicated by the manufacturer (Olympus Life 
and Material Science Europa GmbH, Hamburg, Germany), in the Department of Clinical 
Pathology of Hospital S. João. 
 
2.8 RNA extraction and qRT-PCR 
Total RNA was extracted from MCF-7 cells treated for 24 h with kaempferol 30 µM, using 
Tripure® isolation reagent, according to manufacturer’s instructions (Roche Diagnostics, 
Germany). After removing the culture medium, Tripure® was added and the lysate was 
transferred to an eppendorf tube. Three layers were obtained after chloroform addition. 
The first layer, corresponding to RNA, was then isolated and treated with isopropanol for 
RNA precipitation and was washed with ethanol (75% ethanol in diethylpyrocarbonate 
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(DEPC)). Afterwards, 5 µg of RNA were used as template for complementary DNA 
production through the incubation with Mix dNTP’s at 65ºC for 5 min and then 1 min at 4 
ºC. Afterwards, 5 X First-Strand Buffer (250 mM Tris-HCl, pH 8.3 at room temperature; 
375 mM KCl; 15 mM MgCl2), 0.1 M DTT and RNaseOUT™(40 U/μl) were added and 
incubated at 25 °C during 2 min. Reverse Transcriptase SuperScript II (200 U/μl) was 
added incubated at 25 °C during 10 min, followed by 50 min at 42°C and 70°C for 15 min. 
Samples were then incubated with 1 μl RNAse H for 20 min at 37 °C, to degrade 
unreacted RNA 
The primer pair used for human GLUT1 amplification was 5’- GAT GAT GCG GGA GAA 
GAA GGT-3’ (forward) and 5’- ACA GCG TTGA TGC CAG ACA G-3’ (reverse). The 
amount of GLUT1 mRNA was normalized to the amount of mRNA of the housekeeping 
gene, human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) for which the primer 
pair was as follows: 5’- ATG GAG AAG GCT GGG GCT CAT-3’ (forward) and 5’- GAC 
GAA GAT GGG GGC ATC AG-3’ (reverse). 
mRNA expression levels were analyzed using quantitative reverse-transcritpion PCR 
(qRT-PCR) and was carried out using a LightCycler (Roche, Nutley, NJ, USA). 20 µL 
reactions were set up in microcapillary tubes using 0.5 μM of each primer and 4 μL of 
SYBR Green master mix (LightCycler FastStart DNA MasterPlus SYBR Green I Roche). 
Cycling conditions were as follows: denaturation (95°C for 5 min), amplification and 
quantification [95°C for 10 s, annealing temperature, and 65°C for 10 s, with a single 
fluorescence measurement at the end of the 72°C for 10 s segment] repeated 50 times, 
followed by a melting curve program [(annealing temperature +10)°C for 15 s and 75°C 
with a heating rate of 0.1°C/s and continuous fluorescence measurement], and a cooling 
step to 40°C for 30 s. Data were analyzed using LightCycler® 4.05 analysis software 
(Roche, Mannheim, Germany). 
 
 
2.9 Protein extraction and Western- blotting 
Proteins were extracted from MCF-7 cells treated for 24 h with kaempferol 30 µM, using 
RIPA isolation reagent, according to manufacturer’s instructions (Roche Diagnostics, 
Germany). Protein concentration was quantified using the Pierce BCA Protein Assay Kit. 
For Western blot, the samples (20 μg of protein) were resolved in 12% SDS-PAGE and 
electroblotted onto transfer membranes (HybondTM-C extra, Amersham Biosciences, 
England). Membranes were blocked during 1 h, in TBST (Tris buffered saline with Tween-
20) containing 5% (w/v) nonfat dry milk, washed in TBST and incubated overnight with the 
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primary antibody, rabbit polyclonal anti-GLUT1 (Santa Cruz Biotechnology, Inc.) in a 
1:100 dilution or with β-actin (ABCAM, Cambridge, UK) in a 1:3000 dilution. Then, after 
washing, membranes were incubated for 1 h with secondary anti-rabbit antibody (Santa 
Cruz Biotechnology, Heidelber, Germany) in a 1:2000 dilution. The membranes were 
again washed during 30 min with TBST and then incubated with ECL (Enhanced 
Chemiluminescence) reagent under a chemiluminescence detection system, the 
ChemiDoc XRS (Bio-Rad Laboratories). Band area intensity was quantified using the 
Quantity One software from Bio-Rad. β-Actin was used as loading control. 
 
2.10 Calculation and statistics  
For the analysis of the time-course of 3H-DG uptake, the parameters of equation (2) were 
fitted to the experimental data by a non-linear regression analysis, using a computer-
assisted method (54).  
A(t) =kin/kout(1-e
-kout.t)     (2) 
In equation (2), A(t) represents the accumulation of 3H-DG at time t, kin and kout the rate 
constants for inward and outward transport, respectively, and t the incubation time. Amax is 
defined as the accumulation at steady state (t→∞). 
For the analysis of the saturation curve, the parameters of the Michaelis-Menten equation 
were fitted to the experimental data by using a non-linear regression analysis, using a 
computer-assisted method (54). 
For calculation of IC50 values, the parameters of the Hill equation were fitted to the 
experimental data by using a non-linear regression analysis, using a computer-assisted 
method (54). 
Arithmetic means are given with SEM and geometric means with 95% confidence 
intervals. n represents the number of replicates of at least two different experiments. 
Statistical significance of the difference between two groups was evaluated by the 
Student’s t-test and statistical significance of the difference between three or more groups 
was evaluated by one-way ANOVA test, followed by Bonferroni test. Differences were 
considered to be significant whenever P< 0.05. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER III 
RESULTS 
 
 
26 
 
  
III  RESULTS 
 
27 
 
1. Characterization of 3H-DG uptake by MCF-7 cells 
 
Initially, we characterized uptake of 3H-DG by MCF-7 cells and for that, the variation of 3H-
DG uptake as a function of time (time-course) and substrate concentration (kinetics) was 
investigated. 
 
1.1 Time-course of 3H-DG uptake 
For time-course studies, cells were preincubated for 20 min and then incubated with 3H-
DG at 20 nM for various periods of time, (1, 5, 10, 15, 30 and 90 min), at 37 °C, in the 
absence or presence of cytochalasin B 50 μM (Cyt B; a GLUT inhibitor (55)) + phloridzin 
500 μM (Phz; an SGLT inhibitor (56)). 
As shown in figure 5, MCF-7 takes up 3H-DG in a time-dependent manner. Moreover, 3H-
DG uptake is markedly reduced in the presence of Cyt B + Phz.  
This analysis also showed that the uptake of 3H-DG in control conditions is linear for up to 
6 min of incubation. Therefore, in all subsequent experiments, a 6-min incubation period 
with 3H-DG was used, thus ensuring that the remaining studies will focus on the uptake of 
3H-DG. 
 
Figure 5: Time-course of 
3
H-DG uptake by MCF-7 cells. Cells were incubated at 37 °C and pH 7.4 with 20 
nM 
3
H-DG for various periods of time, under control conditions or in the presence of phloridzin 500 µM + 
cytochalasin B 50 µM (Cyt B 50 + Phz 500). Shown are arithmetic means±SEM (n=4). 
 
 
  1.2 Kinetics 
 
To evaluate the kinetics of uptake of 3H-DG by MCF-7 cells, the cells were incubated with 
increasing concentrations of substrate (0.02-10 000 µM). Figure 6 shows that the uptake 
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of 3H-DG in these cells was saturable, and the Km and the Vmáx were found to be 6.5 ± 0.5 
mM and 63.6 ± 2.3 µmol/mg prot, respectively. 
 
Figure 6: Kinetics of 
3
H-DG uptake by MCF-7 cells. MCF-7 cells were incubated at 37 ºC for 6 min in the 
presence of increasing concentrations of 
3
H-DG (0.2-10 000 µM). Shown are arithmetic means ± SEM (n = 3-
14) 
 
 
After this characterization, it was possible to proceed to the study of 3H-DG uptake 
modulation by polyphenols. 
 
 
 
 
 
2. The acute effect of polyphenols upon 3H-DG uptake  
 
2.1 Evaluation of 3H-DG transport inhibition 
 
In this series of experiments, we investigated the acute effect (26 min) of resveratrol, 
myricetin, genistein, kaempferol, (+) catechin, (-) epicatechin, chrysin and xanthohumol 
(10-100 µM) upon uptake of 3H-DG by MCF-7 cells. 
As shown in Figure 7, four of the tested polyphenols (resveratrol, myricetin, genistein and 
kaempferol) inhibited 3H-DG uptake. By contrast, (+) catechin slightly (by 10-15%) 
increased it, and the others were devoid of significant effect. 
 
Control:  
Km = 6.5 ± 0.5 mM  
Vmáx = 63.6 ± 2.3 µmol/mg.prot 
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Figure 7: The acute effect of several polyphenols on 
3
H-DG uptake. Cells were preincubated for 20 min 
and then incubated for 6 min with 20 nM 
3
H-DG under control conditions (solvent) or in the presence of the 
polyphenols (10 and 100 µM). Polyphenols tested: flavanols (myricetin and kaempferol), flavan-3-ols ((+) 
catechin, (-) epicatechin), an isoflavone (genistein), a flavone (chrysin), a chalchone (xanthohumol) and a 
stilbene (resveratrol). Shown are arithmetic means±SEM. *Significantly different from control (P < 0.05). 
 
 
The inhibitory effect of the polyphenols upon 3H-DG uptake was not related to a decrease 
in cell viability, as none of the polyphenols tested affected LDH leakage, indicating that 
these concentrations did not affect cell membrane integrity and thus cell viability (Fig. 8). 
 
Figure 8: The acute effect of studied polyphenols on cell viability. After a 26 min exposure to polyphenols 
or to solvent (c(DMSO)), MCF-7 cellular viability was determined by quantification of extracellular LDH activity 
(n=12-17). Shown are arithmetic means ±SEM. *Significantly different from control (P < 0.05). 
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Resveratrol, genistein and kaempferol were found to cause the most marked inhibition of 
3H-DG uptake (Fig. 8). Therefore, in the next series of experiments, we tested the effect of 
different concentrations of these compounds (1, 10, 30, 100, 185 or 300 µM) in order to 
calculate their IC50. 
Kaempferol was found to be the most potent inhibitor of 3H-DG uptake by MCF-7 cells, 
with an IC50 of 4.0 (1.6-9.8) µM. The IC50 of genistein and resveratrol was 38.9 (15.2-99.4) 
µM and 67.2 (29.4-153.7) µM, respectively (Fig. 9). 
 
 
Figure 9: Acute effect of different concentrations of kaempferol, resveratrol and genistein. After a 26 
min exposure to genistein, resveratrol and kaempferol, IC50 was determined IC50 results with 7<n<10. Shown 
are geometric means and the corresponding 95% confidence intervals 
 
 
 
 
 
 
Again, the inhibitory effect of these compounds upon 3H-DG uptake is not related to a 
decrease in cell viability or growth (Fig. 10). 
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Figure 10: Effect of resveratrol, genistein and kaempferol on cell viability (A) and cell growth (B). After 
a 26 min exposure to polyphenols or to control (DMSO), MCF7 cellular viability was determined by 
quantification of extracellular LDH activity (n=6-8) and cellular growth was determined by the SRB assay 
(n=12-16). Shown are arithmetic means ±SEM. *Significantly different from control (P < 0.05). 
 
 
 
2.2 Effect upon the kinetics of 3H-DG uptake 
We also evaluated the effect of the most potent of the tested polyphenols, kaempferol, 
upon the kinetics of 3H-DG uptake by MCF-7 cells. For this, cells were incubated with 
increasing concentrations of 3H-DG (0.02-10 000 µM) in the presence of kaempferol or the 
respective solvent. As can be seen in Table 4, KF 100 µM showed an unusual, mixed-type 
inhibitory effect, since it simultaneously increased the Km and the Vmáx.  
 
Table 4: Kinetic parameters of 
3
H-DG uptake by MCF-7 cells in the absence (DMSO) or presence 
of kaempferol 100 µM: Shown are arithmetic means ± SEM (n=3-14). * Significantly different from 
control (DMSO) (P<0.05) 
Compound Km (mM) Vmáx (µmol/mg prot) 
DMSO 6.47 ± 0.5 63.59 ± 2.3 
KF100 µM 15.57 ± 2.4* 106.93 ± 10.6* 
 
 
Considering all these results, we decided to further analyze the effect of KF. For this, we 
studied its chronic effect upon 3H-DG uptake, GLUT1 mRNA and protein expression, and 
upon cell viability and growth. Further, we investigated whether its anticarcinogenic 
(antiproliferative and cytotoxic) effect may be related to inhibition of glucose uptake. 
B - Growth A - Viability 
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3. The chronic effect of kaempferol 
 
 
 
3.1 Modulation of 3H-DG uptake  
 
In a first series of experiments, we characterized the chronic (24 h) effect of kaempferol 
(0.3-30 µM) upon uptake of 3H-DG by MCF-7 cells. 
This compound, when placed in contact with MCF-7 cells for 24h, caused a significant 
inhibition of 3H-DG uptake at 30 µM only (Fig. 11).  
 
 
Figure 11: Chronic effect of kaempferol upon 
3
H-DG uptake. Cells were preincubated for 24 h and then 
incubated for 6 min with 20 nM 
3
H-DG under control conditions or in the presence of kaempferol (KF) at 
different concentrations: 0.3 µM, 1 µM, 3 µM, 10 µM and 30 µM. Shown are arithmetic means±SEM. 
*Significantly different from control (P < 0.05). 
 
 
 
 
3.2 Effect upon lactate production 
 
Considering that these cells in culture perform mainly the Warburg effect, we investigated 
if the decrease in glucose cellular uptake in response to KF 30 µM exposure, as assessed 
by the decrease in 3H-DG uptake, would cause also a decrease in lactate production. 
To clarify this, cells were incubated for 4 or 24h with KF 30 µM, QUE 100 µM or 2-DG 2 
mM. After treatment, the extracellular medium was collected and lactate levels were 
quantified. QUE and 2-DG were used in order to compare their known effects with KF 
effect. 
As shown in Figure 12, exposure of the cells to KF or QUE for 24 h caused a significant 
increase in the amount of extracellular lactate (especially evident for KF). On the contrary, 
2-DG originated a strong decrease in the amount of lactate. When a shorter exposure to 
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these compounds was tested, KF and 2-DG were found to be devoid of effect; QUE, on 
the other hand, originated a decrease in the amount of lactate. 
 
 
 
 
 
 
 
 
Figure 12: Effect of kaempferol (KF), quercetin (QUE) and 2-deoxyglucose (2-DG) upon lactate 
production in MCF-7 cells. Cells were treated at 37ºC for 4 or 24h with kaempferol 30 mM (n = 4-3), 
quercetin 100 mM (n = 3) or 2-DG 2 mM (n = 3-4). Shown are the arithmetic means ± SEM. * P <0.05 vs. 
Control (100%). 
 
 
 
 
3.3 Modulation of GLUT1 mRNA expression 
 
Because KF inhibits 3H-DG transport into MCF-7 cells, we found important to investigate if 
this effect is related to modulation of expression of GLUT1, the main glucose transporter 
in these cells. So, we evaluated its effect upon GLUT1 transcription and translation, to 
realize if it interferes with mRNA synthesis and protein production. 
For that, cells were treated for 24 h with KF 30 µM or with its solvent (DMSO). 
Subsequently, RNA was extracted and after cDNA synthesis, mRNA levels of GLUT1 
were quantified by qPCR. 
The results, shown in Figure 13, clearly show that the expression of GLUT1 mRNA is 
significantly reduced in response to kaempferol. 
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Figure 13: Effect of kaempferol upon GLUT1 mRNA levels in MCF-7 cells. Cells were treated at 37ºC for 
24 h with kaempferol (KF) 30 µM (n = 6) or with its solvent (c(DMSO), dashed line, n = 6). Shown are 
arithmetic means ± SEM of GLUT1 expression relative to the internal control GAPDH. *Significantly different 
from control (P < 0.05). 
 
 
 
3.4 Modulation of GLUT1 protein levels 
 
Next, the effect of KF (30 µM; 24h) upon protein levels was quantified by Western blotting. 
Through Figure 14, it is possible to observe that, although not statistically significant, there 
was a tendency for a decrease in GLUT1 protein levels in the presence of KF. 
 
 
c(DMSO)  KF 30 µM 
GLUT1 
 
 
 
β-actin 
  
     
       
 326.9 ± 79.3 221.0 ± 104.5 
 
Figure 14: Modulation of GLUT1 protein levels by kaempferol in MCF-7 cells. Cells were treated at 37 ºC 
for 24 h with kaempferol (KF) 30 µM (n = 5) or with its solvent (c(DMSO), dashed line, n = 6). β-actin was used 
in order to normalize the results. Shown are arithmetic means ± SEM. 
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4. Antiproliferative and cytotoxic properties of kaempferol 
In the next series of experiments, we aimed to investigate if KF presents an 
anticarcinogenic effect on MCF-7 cells and if this effect is related with inhibition of 3H-DG 
uptake. 
 
 
 4.1 Effect upon cell proliferation rate 
The rate of cell proliferation was evaluated by measuring the incorporation of 3H-thymidine 
by MCF-7 cells. As can be seen in Figure 15, KF 30 µM had no effect on MCF-7 
proliferation rate, but a higher concentration (100 µM) markedly reduced it. 
 
Figure 15: Effect of kaempferol upon cell proliferation rate of MCF-7 cells. Cells were cultured for 24h 
with DMSO (n = 9) or kaempferol (KF) 30-100 µM (n = 9). Shown are arithmetic means ± SEM. * P <0.05 vs. 
Control (100%).  
 
 
4.2 Effect upon cell integrity 
As shown in Figure 16, KF 100 µM, but not KF 30 µM, caused a significant increase in 
LDH leakage (Fig. 16, A) and a significant decrease in cell growth (Fig.16, B). 
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Figure 16: Effect of kaempferol on viability (A) and growth (B). After a 24h exposure to kaempferol (KF) at 
30-100 µM or to its solvent (c(DMSO)), MCF-7 cellular viability was determined by quantification of 
extracellular LDH activity (n=12) and cellular growth was determined by the SRB assay (n=12). Shown are 
arithmetic means ±SEM. *Significantly different from control (P < 0.05). 
 
 
 
5. Relationship between GLUT-mediated glucose transport and the 
antiproliferative and cytotoxic properties of kaempferol 
 
In the last series of experiments, we investigated if inhibition of GLUT-mediated glucose 
transport is involved in the antiproliferative and cytotoxic effect of KF. For this, cells were 
exposed, during 24 h, to KF 100 µM or to its solvent (DMSO) in HMBS buffer with different 
glucose concentrations: 1 mM (Low Glucose – LG), 5.56 mM (Normal Glucose – NG) or 
20 mM (High Glucose – HG).  
 
 
5.1 Mimetization of kaempferol effect by Low Glucose-conditions 
Interestingly, low glucose conditions mimic the effect of KF upon cell viability (Fig. 17, A) 
and growth (Fig. 17, B). This result is in agreement with the hypothesis that the 
antiproliferative and cytotoxic effect of KF is dependent on inhibition of glucose entry into 
the cells. 
 
 
 
 
A – Viability B – Growth 
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Figure 17: Mimetization of the effect of kaempferol on cell viability (A) and cell growth (B) by low 
glucose-conditions. Cells were exposed for 24 h to kaempferol (KF) at 100 µM or to its solvent (DMSO) in 
Normal Glucose-conditions (NG, 5.56 mM) or in low Glucose-conditions (LG, 1 mM). MCF-7 cellular viability 
was determined by quantification of extracellular LDH activity (n=10-11) and cellular growth was determined 
by quantification of whole cellular protein with SRB (n=12). Shown are arithmetic means ±SEM. *Significantly 
different from control (P < 0.05). 
 
 
5.2 Reversal of the effect of kaempferol by High Glucose conditions 
A further confirmation of the conclusion that the cytotoxic effect of KF is dependent on 
inhibition of glucose entry into the cells is the observation that high glucose conditions 
were able to reverse the effect of KF in relation to cell viability (Fig. 18). However, no 
reversal could be found in relation to cell growth (results not shown). 
 
Figure 18: Reversal of the effect of kaempferol on cell viability by high glucose-conditions. Cells were 
exposed for 24 h to kaempferol (KF) at 100 µM or to its solvent (DMSO) in Normal Glucose-conditions (NG, 
5.56 mM) or in High Glucose-conditions (HG, 20 mM). MCF-7 cellular viability was determined by 
quantification of extracellular LDH activity (n=10-12). Shown are arithmetic means ±SEM. *Significantly 
different from control (P < 0.05). 
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Breast cancer is one of the most devastating human diseases and some of the existent 
therapies are very toxic to normal cells. So, it is imperative to search for novel therapeutic 
compounds, especially natural compounds, since they are safe and have a favorable 
toxicity profile, which makes them suitable (57, 58). 
Cancer cells present an altered metabolism, with an increased rate of glucose uptake and 
glycolysis in aerobic conditions instead of oxidative metabolism (the Warburg effect) (25). 
As a cell model of breast cancer, a human cell line derived from a malignant 
adenocarcinoma breast tissue, the MCF-7 cells, was used. As is already known, these 
cells are a prominent model system since they preserve several ideal characteristics 
particular to the mammary epithelium (59, 60). 
This study was designed in order to characterize glucose transport in breast cancer cells, 
to provide information about the effect of polyphenols on glucose uptake, and to 
investigate inhibition of glucose uptake as being involved in the effect of these compounds 
on cell viability and growth.  
For glucose transport experiments, 2-deoxy-D-glucose (2-DG) was used, since it is a 
glucose analog efficiently transported by GLUT family members but a very poor SGLT 
substrate (48) and cannot be metabolized by phosphoglucose isomerase (61).  
According to the results obtained, 3H-DG uptake in MCF-7 cells was: (1) time-dependent; 
(2) saturable (with an Km of 6.5 ± 1.5 mM and a Vmáx of 63.6 ± 6.8 µmol/mg prot); (3) 
inhibited by cytochalasin B (CYT B), an inhibitor of glucose facilitative transporters 
(GLUTs) (55) and by phlorizin (PHZ), an inhibitor of sodium-dependent glucose 
transporters (SGLTs) (56). However, we speculate that SGLTs are not involved in this 
process. Previous studies from our group (21) have demonstrated that 3H-DG uptake by 
MCF-7 cells does not involve SGLT1, albeit being inhibited by PHZ. This conclusion was 
based on the fact that not only DG is a poor substrate of SGLT1, but also PHZ is a 
glucoside. So, the authors speculated that this flavonoid may be an unspecific competitive 
inhibitor of glucose transport and not a specific inhibitor of SGLT1 (21). These data 
suggest that, in these cells, glucose uptake is mediated by GLUTs. GLUT1 is likely to be 
the main mediator of glucose uptake by MCF-7 cells, since it is highly expressed in this 
cell line and it is known to be critical for glucose uptake in tumors (18-20). 
Dietary polyphenols are known to possess cancer preventive and anticarcinogenic effects 
(31). These compounds are abundant in our diet, but their health effects are obviously 
influenced by the amount consumed and by their bioavailability. Recently, our group 
verified that the polyphenols quercetin (a flavanol) and epigallocatechin gallate (a flavan-
3-ol) inhibited glucose uptake by MCF-7 cells (21). So, we decided to investigate if other 
polyphenols could also interfere with glucose uptake by these cells. Thus, in the second 
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part of this work, we studied the modulation of 3H-DG uptake by several polyphenols after 
an acute exposure: some flavanols (myricetin and kaempferol) and flavan-3-ols ((+) 
catechin and (-) epicatechin), a flavone (chrysin), an isoflavone (genistein), a chalchone 
(xanthohumol) and a stilbene (resveratrol). As mentioned in the Introduction, these 
polyphenols were chosen because several studies have shown their anticancer effects: 
genistein (45), kaempferol (62), resveratrol (47), xanthohumol (46), myricetin (40), (+) 
catechin and (-) epicatechin (21) and chrysin (44). 
When MCF-7 cells were acutely treated (26 min) with myricetin, genistein, resveratrol, and 
kaempferol (KF) (10-100 µM), a concentration-dependent inhibition of 3H-DG uptake was 
observed. By contrast, (+) catechin slightly (by 10-15%) increased it. Through this it is 
possible to conclude that polyphenols belonging to different polyphenolic classes are able 
to impair glucose uptake and that their effects are strongly influenced by their chemical 
structure. This is evident in the disparate results of (+) catechin, (-) epicatechin and the 
epigallocatechin gallate, since they are at the same polyphenolic family and present 
different behaviors.  
The cell integrity tests were important to prove that the above mentioned effects were not 
due to cellular death. So, by proving that the studied polyphenols don’t interfere with 
viability and growth of MCF-7 cells (except genistein that seems to increase cell growth) 
we can conclude that their effect upon 3H-DG uptake is specific. 
Determination of IC50 for resveratrol, genistein and KF led us to conclude that KF was the 
most potent inhibitor of 3H-DG uptake by MCF7 cells, with an IC50 of 4.0 (1.6-9.8) µM (the 
IC50 of genistein and resveratrol was 38.9 (15.2-99.4) µM and 67.2 (29.4-153.7) µM, 
respectively). So, KF was chosen as the polyphenol to investigate in the remaining 
studies. 
Flavonoids are classified according to their level of oxidation and to the pattern of 
substitution at the C ring. Individual compounds within a class differ in the arrangements 
of hydroxyl groups, which increase the water solubility (29, 31). KF (3,5,7-trihydroxy-2-(4-
hydroxyphenyl)-4H-1-benzopyran-4-one) is a flavonol and normally is found in tea, 
broccoli, cabbage, kale, beans, endive, leek, tomato, strawberries and grapes (63). 
According to a Japanese study, the average daily intake (from japanese food) per capita 
of KF is 4.9 mg (64). However, in a Spanish study, it is estimated that human dietary 
intake may be approximately 10 mg/day (63).  Normally, this compound is present at 26 ± 
7 µg/d in urine. However these levels depend on the type of food consumed and on the 
amount of intake (65). KF and all the flavonoids are mostly found in food as O-glycosides 
and therefore these compounds need to be deglycosylated in order to be absorbed. 
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Some previous studies have found a link between the consumption of foods containing KF 
and a reduced risk of developing cancer. Some suggest that KF inhibits MCF-7 breast 
cancer cell proliferation through activation of the caspase cascade pathway (66); others 
suggest that KF is an antioxidant and can prevent lipid peroxidation, reducing ROS levels; 
that it is anti-inflammatory or that it inhibits angiogenesis in vitro and metastasis (63). 
Analysis of the effect of KF upon the kinetic parameters of 3H-DG uptake showed a very 
unusual effect, since it simultaneously increases the Km and the Vmáx of 
3H-DG uptake. So, 
KF seems to decrease the affinity while increasing the capacity of 3H-DG uptake. In other 
words, KF appears to inhibit uptake of a low concentration of 3H-DG while increasing 
uptake of a high concentration. Gonçalves et al. (2009) demonstrated the same effect with 
acetylsalicylic acid in modulation of butyrate transport in Caco-2 cells (67). 
When MCF-7 cells were subjected to a chronic treatment (24h) with KF, it was verified 
that this flavonoid also inhibits 3H-DG uptake (IC50 of 13.6 (2.8-66.9) µM), although less 
markedly than in the acute treatment. The chronic effect of KF was concordant with the 
study of Filomeni et al. (2010), that demonstrated a block in cellular uptake of glucose by 
this flavonoid in HeLa cells (61). However, this is the first work showing an inhibitory effect 
of KF upon glucose uptake in BrC cells. 
We next decided to deepen knowledge on the KF effect at GLUT1 transcriptional and 
translational level. qRT-PCR results showed a significant decrease in the mRNA 
expression levels of GLUT1 after treatment with KF. A similar decrease in GLUT1 protein 
levels was observed in western-blot, although not statistically significant. The decreasing 
levels of mRNA and protein production are concordant with the inhibitory effect of KF on 
3H-DG transport, suggesting that reduction of 3H-DG transport is due to downregulation of 
GLUT1 gene and protein expression.  
Being glucose a main energy source for cancer cells, and so being necessary for their 
survival, glucose deprivation is expected to have a negative impact in cellular viability and 
growth. This fact was described by Munõz-Pinedo et al. (2003), who proved that the 
absence of glucose induces apoptosis in MCF-7 cells (68). Also, it is known that in human 
BrC, high GLUT1 expression tends to correlate with high proliferative activity and 
histological score (69). 
So, in the last part of this work, we decided to investigate the effect of KF upon cell 
viability and growth and the relationship between inhibition of glucose uptake by KF and 
its effect upon cell viability and growth.  
Chronic (24 h) treatment of the cells with KF (100 µM) caused a significant decrease in 
cell viability (as assessed by the quantification of extracellular lactate dehydrogenase 
activity) and growth (as assessed by the SRB assay and by quantification of 3H-thymidine 
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incorporation). So, KF presents antiproliferative and cytotoxic effects in MCF-7 cells. 
These results are in line with others studies, which demonstrated that KF is a compound 
which has effect in several areas, such as signal transduction, cell cycle, angiogenesis, 
metastasis and inflammation, and that it shows antiproliferative and cytotoxic effects in 
tumor cells. (62).  
As already known, cancer cells produce lactate when they metabolize glucose, in order to 
produce their energy faster (70). So, we decided to analyze if inhibition of GLUT1 by KF 
would lead to a decrease in lactate production. Unexpectedly, exposure of cells for 24h to 
KF induced a very marked increase in the amount of extracellular lactate. In order to 
further investigate this finding, we also analyzed the effect of QUE and of 2-DG (since 
QUE is a known GLUT and MCT1 inhibitor and 2-DG is a GLUT inhibitor) and we tested a 
shorter exposure time. From the results obtained, we concluded that the increase in 
extracellular lactate concentration observed with KF (and, albeit less markedly, with QUE) 
treatment may be due to an inhibition of lactate reuptake, mediated by MCT1, in MCF7 
cells (70). On the contrary, 2-DG, which is solely a GLUT1 inhibitor, caused a decrease in 
extracellular lactate. 
Studies suggest that MCT1 (present in aerobic cells and responsible for the uptake of 
lactate) inhibition causes a switch from lactate-fuelled respiration to glycolysis. Aerobic 
tumor cells can now use glucose to fuel glycolysis and secrete lactate and hypoxic tumor 
cells, located far from blood vessels, die due to starved glucose and consequently energy 
failure (70, 71). In our study, cells don’t have glucose due to GLUT1 block by KF and with 
the block of MCT1, they also don’t have lactate, so these cells apparently don’t have an 
energy source.  
In the last part of this work, the relationship between inhibition of glucose uptake and the 
antiproliferative and cytotoxic effect of KF was investigated, by analyzing this effect of KF 
under several distinct concentrations of glucose. With these data, it was verified that low 
glucose mimics the effect of KF upon cell viability and growth, and that the effect of KF 
upon cell viability was reversed by high glucose. This observation is in agreement with 
Elstrom et al. (2004), who believe that inhibition of basal glucose transport may be a 
potential strategy for cancer treatment, because cancer cells are very sensitive to glucose 
concentration changes (72). In fact, glucose deprivation may induce kinases activation, 
changes in the redox state of the cell, or generation of free radicals and consequently 
induces cell death, making cells more fragile (73). On the other hand, elevated levels of 
glucose may promote increased glucose uptake (74, 75). These observations further 
validate GLUT1 as the main mediator of glucose transport in MCF-7 cells, since it is highly 
expressed in these cells and can be easily modulated by the presence of low or high 
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glucose (69). Taking all these into account, low glucose has a better treatment outcome 
comparing with high glucose.  
So, in this work, we demonstrated that in MCF-7 cells KF impairs glucose utilization, 
which is associated with an anticarcinogenic effect. Some previous studies already 
showed a cytotoxic, antiproliferative and antitumoral effect of KF in ovarian (76), breast 
(77) and pancreatic cancer cells (78), but none related it with glucose utilization by cancer 
cells. 
Summarizing, we suggest that KF directly inhibits GLUT1 and MCT1 and that cellular 
glucose and lactate deprivation induces several downstream effects such as cytotoxicity 
and proliferation arrest. 
Taking all the results of this work into account, it is possible to create a model that 
proposes the effect of KF in MCF-7 cells (Fig. 19). 
 
 
 
 
 
 
 
 
 
 
Figure 19: Model of kaempferol-induced anticancer effects. Kaempferol inhibits glucose and lactate 
uptake favoring the cytotoxic and antiproliferative effects.  
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Several polyphenols, belonging to different polyphenolic classes, impair glucose uptake 
by MCF-7 cells. The effect of these polyphenols upon glucose uptake does not appear to 
be related to their chemical structure. 
As a whole, the data suggest that KF is the most potent inhibitor of glucose uptake, 
inhibiting GLUT1, which induces several downstream effects such as a decrease in 
glucose metabolism, cytotoxicity and proliferation arrest. 
Overall, this study contributes to the elucidation of the mechanism involved in glucose 
transport in breast cancer cells and to a deeper knowledge of the health promoting effects 
of this flavonoid and its potential as therapeutic agent/adjuvant in breast cancer. 
A link between cancer risk and the intake of some nutrients is well established. However, 
it is difficult to determine the effect of a single nutrient/compound in cancer prevention, 
because its effect may result from an interaction with other components present in food. 
So, in the future it is important to study KF interactions in the food matrix, its bioavailability 
and its effects at concentrations usually found in plasma. 
Cancer cells are characterized by having a reverse pH gradient, since they present a 
higher internal pH (>7.4) and a lower external pH (6.7–7.1), which do not occur in normal 
cells. The internal pH, when high, is responsible for cell proliferation, evasion of apoptosis, 
metabolic adaptation and cell migration. On the other hand, a decreased external pH 
leads to the remodeling of extracellular matrix (ECM) and stimulates acid-activated 
proteases (79). In cells treated with KF, the extracellular pH is very low. So, from the 
results obtained we can raise the following questions: because MCT1 blockade leads to a 
decrease in pHe, can this contribute to tumor growth? There are some compensatory 
mechanisms associated to this effect? To answer them, more investigation is needed. 
As it was demonstrate by Luo et al. (2012), KF nanoparticles achieve a strong and 
selective inhibition of ovarian cancer cell viability. Taking into account the nanotechnology 
evolution, it would be interesting also to analyze this option in BrC, since it seems to be a 
promising therapy (76). 
Knowledge from future experiments, together with data obtained from “in vivo” studies, 
might help to sustain future nutritional recommendations in order to improve health. 
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Tenho a certeza de que hoje somos senhores 
do nosso destino, que a tarefa que temos 
perante nós não está acima das nossas 
forças; que as dores e dificuldades não estão 
para lá das nossas capacidades de 
resistência física. Enquanto tivermos fé na 
nossa própria causa e uma indomitável 
vontade de ganhar, a vitória não nos será 
negada. 
Winston Churchill 
